NTLA Stock: Price, Earnings History and SEC Filings
Intellia Therapeutics, Inc. (NTLA) last traded at $12.47, down 5.74% on the latest session and up 3.4% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.80 against an analyst estimate of $-0.80, a beat of 0.0%.
$12.47 -5.74%
1 month+3.40%
52-week high$18.48
52-week low$7.95
Volume4.09M
ExchangeNasdaqGM
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
NTLA earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $-0.80 | $-0.80 | +0.00% |
| Mar 2026 | May 11, 2026 | $-0.81 | $-0.92 | +11.96% |
| Dec 2025 | Feb 26, 2026 | $-0.83 | $-0.99 | +16.16% |
| Sep 2025 | Nov 6, 2025 | $-0.92 | $-1.02 | +9.80% |
NTLA beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for NTLA
SEC filing data is not available right now. You can search for NTLA on SEC EDGAR.
NTLA news
- Exelixis (EXEL) Surpasses Q3 Earnings and Revenue EstimatesOct 29, 2026 · finance.yahoo.com
- Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026Oct 29, 2026 · finance.yahoo.com
- Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Oct 28, 2026 · finance.yahoo.com
- PRME, BEAM, EDIT, NTLA, CRSP stocks gain as FDA signals faster route for patient-specific gene editsOct 28, 2026 · msn.com
- Biogen Inc. (BIIB) Tops Q3 Earnings and Revenue EstimatesOct 28, 2026 · finance.yahoo.com
- Has The Story Under Krystal Biotech Stock Run Out?Oct 28, 2026 · trefis.com
- The Zacks Analyst Blog Highlights BridgeBio Pharma, Intellia Therapeutics, Biogen and Viking TherapeuticsOct 21, 2026 · finance.yahoo.com
- 4 Biotech Stocks With Promising Late-Stage Drug Pipelines to Watch NowOct 20, 2026 · finance.yahoo.com
About Intellia Therapeutics, Inc.
Intellia Therapeutics, Inc. (NTLA) is a US-listed public company on Nasdaq.